你即將離開本站

並前往https://www.nasdaq.com/articles/orphazyme-orph-up-on-plans-of-nda-resubmission-for-rare-drug

Orphazyme (ORPH) Up on Plans of NDA Resubmission for ...

In June 2021, the FDA issued a Complete Response Letter (“CRL”) to the NDA for arimoclomol for the treatment of NPC. The company had a Type A ...

確定！ 回上一頁

查詢 「ORPH FDA」的人也找了：

  1. ORPH FDA approval
    2.
  2. Orphazyme A/S news
    3.
  3. Orphazyme
    4.
  4. FDA IND database
    5.
  5. Orphan drug Act
    6.
  6. ORPH stock
    7.
  7. Orphan FDA
    8.
  8. Orphazyme as adr
    9.